eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for Esophageal and Esophagogastric Junction Cancers
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Esophageal and Esophagogastric Junction Cancers. These NCCN Guidelines® are currently available as Version 4.2024.
Link directly to the Updates section of the NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers
Principles of Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease
ESOPH-F 6 of 22 and ESOPH-F 7 of 22
- Adenocarcinoma and Squamous Cell Carcinoma
- Second-line or Subsequent Therapy; Useful in Certain Circumstances: Repotrectinib added as an option for NTRK gene fusion-positive tumors
- Footnote j is new: Repotrectinib can be used in patients whose disease progressed on a prior NTRK targeted therapy.
Principles of Systemic Therapy-Regimens and Dosing Schedules
ESOPH-F 18 of 22
- Second-line or Subsequent Therapy; Useful in Certain Circumstances: The following dosing schedule was added:
Repotrectinib
160 mg PO Daily Days 1-14 of Cycle 1
160 mg PO BID Days 15-28 of Cycle 1
160 mg PO BID Days 1-28 of Cycle 2 and beyond
Cycled every 28 days
Principles of Systemic Therapy-References
ESOPH-F 22 of 22
- New reference added: Solomon BJ, Drilon A, Lin JJ, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology 2023;34:S787-S788.
NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Gastric Cancer. These NCCN Guidelines are currently available as Version 3.2024.
Link directly to the Updates section of the NCCN Guidelines: Gastric Cancer
Principles of Systemic Therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease
GAST-F 5 of 20
- Second-line or Subsequent Therapy; Useful in Certain Circumstances: Repotrectinib added as an option for NTRK gene fusion-positive tumors
- Footnote k is new: Repotrectinib can be used in patients whose disease progressed on a prior NTRK targeted therapy.
Principles of Systemic Therapy-Regimens and Dosing Schedules
GAST-F 16 of 20
- Second-line or Subsequent Therapy; Useful in Certain Circumstances: The following dosing schedule was added:
Repotrectinib
160 mg PO Daily Days 1-14 of Cycle 1
160 mg PO BID Days 15-28 of Cycle 1
160 mg PO BID Days 1-28 of Cycle 2 and beyond
Cycled every 28 days
Principles of Systemic Therapy-References
GAST-F 19 of 20
- New reference added: Solomon BJ, Drilon A, Lin JJ, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology 2023;34:S787-S788.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.